Salud financiera de hoja de balance de Intra-Cellular Therapies

Salud financiera controles de criterios 5/6

Intra-Cellular Therapies tiene un patrimonio de los accionistas total de $1.1B y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $1.3B y $179.6M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$1.01b
Patrimonio	US$1.14b
Total pasivo	US$179.62m
Activos totales	US$1.32b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($1.3B) de 23I superan a sus pasivos a corto plazo ($166.1M).

Pasivo a largo plazo: Los activos a corto plazo de 23I ($1.3B) superan a sus pasivos a largo plazo ($13.5M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 23I está libre de deudas.

Reducción de la deuda: 23I no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 23I tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si 23I tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.

Salud financiera de hoja de balance de Intra-Cellular Therapies

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia

Intra-Cellular Therapies, Inc. Raises Financial Guidance for the Full Year 2024

Third quarter 2024 earnings released: US$0.25 loss per share (vs US$0.25 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.45 loss in 2Q 2023)

Intra-Cellular Therapies, Inc. Raises Sales Guidance for 2024

Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from Russell 2000 Dynamic Index

Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.16 loss per share (vs US$0.46 loss in 1Q 2023)

Intra-Cellular Therapies, Inc., Annual General Meeting, Jun 14, 2024

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $500.000068 million.

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $500.000068 million.

New minor risk - Shareholder dilution

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies, Inc. Announces Retirement of Larry Hineline as Chief Financial Officer

Full year 2023 earnings released: US$1.46 loss per share (vs US$2.73 loss in FY 2022)

New minor risk - Shareholder dilution

Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2024

Forecast to breakeven in 2025

EVP & Chief Commercial Officer recently sold €801k worth of stock

Intra-Cellular Therapies, Inc. Provides Sales Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.57 loss in 3Q 2022)

Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.45 loss per share (vs US$0.92 loss in 2Q 2022)

Forecast to breakeven in 2025

Intra-Cellular Therapies, Inc. Announces CAPLYTA Data Presentations At the American Society of Clinical Psychopharmacology Annual Meeting

Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.46 loss per share (vs US$0.78 loss in 1Q 2022)

Full year 2022 earnings released: US$2.73 loss per share (vs US$3.50 loss in FY 2021)

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Independent Director recently sold €240k worth of stock

Independent Director recently sold €523k worth of stock

Independent Director recently sold €523k worth of stock

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$0.94 loss in 3Q 2021)

Independent Director recently sold €573k worth of stock

Second quarter 2022 earnings released: US$0.92 loss per share (vs US$0.85 loss in 2Q 2021)

First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.65 loss in 1Q 2021)

Intra-Cellular Therapies, Inc. Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations

Intra-Cellular Therapies, Inc., Annual General Meeting, Jun 09, 2022

Independent Director recently sold €736k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Forecast to breakeven in 2024

Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults

Third quarter 2021 earnings released: US$0.94 loss per share (vs US$0.79 loss in 3Q 2020)

Intra-Cellular Therapies, Inc. Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry

Second quarter 2021 earnings released: US$0.85 loss per share (vs US$0.96 loss in 2Q 2020)

Forecast to breakeven in 2023

High number of new directors

Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from Russell 3000E Value Index

First quarter 2021 earnings released: US$0.65 loss per share (vs US$0.73 loss in 1Q 2020)

Intra-Cellular Therapies Announces FDA Acceptance of Caplyta (Lumateperone) SNDAs for the Treatment of Bipolar Depression

Revenue beats expectations

Intra-Cellular Therapies Announces Expansion of Pipeline with the Introduction of New Molecular Entity, ITI-1284

Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression

New 90-day high: €32.85

New 90-day high: €29.02

Intra-Cellular Therapies, Inc. Announces the Publication of Results from the CAPLYTA Clinical Trial (ITI-007-303)

New 90-day high: €27.41

Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder

New 90-day high: €23.82

Senior VP of Finance recently sold €174k worth of stock

Revenue beats expectations

Intra-Cellular Therapies, Inc. Announces Executive Changes

Intra-Cellular Therapies, Inc. Announces Executive Changes

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $350.00001 million.

New 90-day low - €15.16

New 90-day low - €16.08

First half earnings released

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera